Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Tharimmune, Inc.

Get SEC filing alerts via email and in your feed for Tharimmune, Inc.

THAR

Tharimmune, Inc.

About Tharimmune, Inc.

Tharimmune is a biotech company focused on developing therapies for inflammatory and immunologic conditions with high unmet needs. Its pipeline includes novel biologics, bispecific antibodies, and innovative delivery systems targeting liver-related pruritus, cancer, and immune checkpoints. The company leverages proprietary technologies, strategic collaborations, and a clinical-stage portfolio to address complex diseases, aiming to improve treatment efficacy and patient outcomes in high-value therapeutic areas.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Tharimmune, Inc.

1
1
Tharimmune, Inc. Canton Strategic Holdings Reports $47.3 Million Net Loss and Launches Digital Asset Strategy

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Tharimmune, Inc. Tharimmune Reports $42.1 Million Net Loss Amid Shift to Digital Asset Management

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Tharimmune, Inc. Tharimmune Reports Decreased Net Loss and Increased Assets in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Tharimmune, Inc. Tharimmune Reports Q2 2025 Financial Results with Reduced Losses and Ongoing Funding Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Tharimmune, Inc. Tharimmune Reports $2.54 Million Net Loss and Increased Operating Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Tharimmune, Inc. Tharimmune Reports $12.2 Million Net Loss for Fiscal Year 2024, Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Tharimmune, Inc. Tharimmune Reports Significant Financial Decline, Net Loss, and Concerns Over Going Concern Status

Via official filing (AI summary) | over 1 year ago | 0 comments